Name: China Supplier High Quality Best Price Zoledronic Acid CAS 118072-93-8
Brand: Wuhan Fortuna Chemical Co., Ltd.

Specifications of Zoledronic Acid CAS 118072-93-8

Items	Specification	Result
Assay	≥98%	99%
Apperance	White crystalline powder	Complies
PH	2.0~4.0	2.5
Heavy metals	≤10ppm	Complies
Total impurities	≤0.5%	0.06%
Single impurity	≤0.1%	0.04%
Unspecific impurity	≤0.1%	0.06%
Water	5.0%-7.0%	5.1%

Parameters of Zoledronic Acid CAS 118072-93-8

Product parameters
Cas number:	118072-93-8
Appearance:	White crystalline powder
Purity:	98%min
Package details:	10g,100g,1kg/foil bag
Brand:	Fortunachem

Zoledronic acid is a potent bisphosphonate medication used primarily to strengthen bones and prevent bone loss. It works by slowing down the breakdown of bone, a natural process known as resorption.

It is most commonly administered by intravenous (IV) infusion, meaning it is given slowly through a vein, typically over at least 15 minutes. Its brand names include Zometa® and Reclast®, with Aclasta® being another common name outside the US.

How Does It Work?

To understand how it works, it's helpful to know a little about bone biology:

Bones are living tissue that are constantly being broken down and rebuilt by cells called osteoclasts (which resorb bone) and osteoblasts (which form new bone).
In conditions like osteoporosis or cancer that has spread to the bone, osteoclasts become overactive, leading to excessive bone loss, weakness, and fractures.

Zoledronic acid works by:

Inhibiting Osteoclasts: It attaches to the bone surface at sites of active resorption.

Disrupting Function: It is taken up by the overactive osteoclasts and interferes with their internal processes.

Promoting Cell Death: This disruption ultimately leads to the death (apoptosis) of the osteoclasts.

By reducing osteoclast activity, the balance shifts in favor of bone-building, leading to an increase in bone mineral density and stronger, more resilient bones.

What is it Used For? (Indications)

Zoledronic acid is used for several conditions related to bone loss and complications:

1. Osteoporosis (Reclast/Aclasta):

Treatment of osteoporosis in postmenopausal women and men.
Prevention of new fractures in patients who have recently had a low-trauma hip fracture.
Treatment and prevention of glucocorticoid-induced osteoporosis (bone loss caused by steroid medications like prednisone).

2. Cancer-Related Conditions (Zometa):

Prevention of Skeletal-Related Events (SREs) in patients with cancer that has metastasized (spread) to the bone (e.g., from breast cancer, prostate cancer, lung cancer). SREs include:
Pathological fractures (broken bones due to disease, not injury)
Spinal cord compression
The need for radiation or surgery to the bone
Treatment of high calcium levels in the blood (hypercalcemia of malignancy) caused by cancer.
Treatment of multiple myeloma (a cancer of plasma cells in the bone marrow) and bone metastases from solid tumors.

3. Paget's Disease of Bone (Reclast):

A chronic disorder that disrupts the normal bone remodeling process, leading to enlarged and misshapen bones. Zoledronic acid is used to treat this condition.

Administration and Dosage

Route: Intravenous (IV) infusion.
Frequency:
For osteoporosis: Typically once a year.
For cancer indications: Usually every 3 to 4 weeks.
Important Pre-Infusion Check: Before the infusion, kidney function must be tested, as the drug is cleared by the kidneys and can be harmful if they are not working properly.

Important Side Effects and Risks

While effective, zoledronic acid has several important potential side effects that require monitoring:

Acute Phase Reaction (Very Common): Often occurs within 24-72 hours after the first infusion. Symptoms are flu-like and include:

Fever and chills
Muscle and joint pain
Headache
Fatigue
These symptoms are usually mild to moderate and resolve on their own within a few days. They are less common with subsequent doses.
Kidney Toxicity (Nephrotoxicity): Can impair kidney function. This is why kidney function is checked before each dose, and the infusion is given slowly.
Low Calcium Levels (Hypocalcemia): The drug can lower calcium levels in the blood. Patients are often advised to take calcium and vitamin D supplements before and after treatment to prevent this.
Osteonecrosis of the Jaw (ONJ): A rare but serious condition where a section of the jawbone loses its blood supply and dies. Risk is higher for cancer patients receiving frequent, higher doses, especially after dental procedures (like tooth extraction). Good oral hygiene and a dental exam before starting treatment are crucial.
Atypical Femur Fractures: Very rare fractures in the thigh bone (femur) that can occur with little or no trauma. Any new or unusual pain in the hip, groin, or thigh should be reported to a doctor immediately.

Key Contraindications (Who Should NOT Take It)

Patients with severe kidney impairment.
Patients with low blood calcium (hypocalcemia). This must be corrected first.
Pregnant or breastfeeding women.
People who are allergic to zoledronic acid or any other bisphosphonate.

Summary

Aspect	Description
Drug Class	Bisphosphonate
Primary Use	To strengthen bone and prevent fractures
Mechanism	Inhibits bone-breakdown cells (osteoclasts)
Common Brands	Reclast®, Zometa®, Aclasta®
Administration	Intravenous (IV) infusion (once a year for osteoporosis)
Key Risks	Acute flu-like symptoms, kidney issues, low calcium, osteonecrosis of the jaw (rare)

Disclaimer: This information is for educational purposes only. Always consult with a qualified healthcare professional for diagnosis, treatment decisions, and personalized medical advice.